Talis Biomedical Corp

NASDAQ:TLISUnited States

Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

Contact Information

Headquarters

1100 Island Drive, Suite 101REDWOOD CITY, CA, United States 94065

Phone

650-433-3000

Fax

302-636-5454

Executives

President, Chief Scientific Officer

Andrew Lukowiak

Chief Executive Officer, Director

Robert Kelley

Co-Founder, Director

Rustem Ismagilov

Interim Chief Financial Officer

Rebecca Markovich

Lead Independent Director

Kimberly Popovits